Palboxen 125 (Palbociclib)

Description

Palboxen 125 mg (Palbociclib) sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. This medicine is manufactured by Everest Pharmaceutical Limited.

 

Frequently Asked Questions About Palboxen

---

Q: What is Palboxen 125 mg (palbociclib)?

Palboxen 125 is a targeted or biological therapy drug. When used to treat breast cancer, palboxen is taken alongside hormone (endocrine) therapy. Palbociclib is the drug’s non-branded name. Its brand name is Ibrance. It belongs to a group of drugs called CDK (cyclin-dependent kinase) inhibitors.

 

Q: How Palboxen 125 mg Work?

Palboxen 125 mg works by blocking these proteins, helping to stop the cancer cells from growing and dividing. When combined with hormone therapies that block the effects of estrogen on cancer cells, palbociclib helps to delay the growth of ER+, HER2-negative breast cancer. for more information visit

 

Q: What happens if I miss a dose of palboxen?

If you miss a palbociclib dose or are sick (vomit) soon after taking it, do not take an extra dose to make up for the one you missed. Keep to your usual amount and speak to someone in your treatment team.

 

---

Dosage & Administration: The recommended dose of Palboxen is a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days of treatment to comprise a complete cycle of 28 days. palboxen (Palbociclib) should be taken with food. Administer the recommended dose of an aromatase inhibitor when given with Palboxen 125 mg (Palbociclib). Please refer to the Full Prescribing Information for the aromatase inhibitor being used. When given with (Palbociclib), the recommended dose of fulvestrant is 500 mg administered on Days 1,15, 29, and once monthly thereafter. Please refer to the Full Prescribing Information of fulvestrant. Pre/perimenopausal women treated with the combination of Palboxen 125 mg (Palbociclib) plus fulvestrant therapy should be treated with luteinizing hormone-releasing hormone (LHRH) agonists according to current clinical practice standards.

 

Overdose: If an overdose occurs the patient must be monitored for evidence of toxicity. Treatment of overdose includes monitoring of vital signs as well as observation of the clinical status of the patient.

 

Storage: Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.